Efficacy analysis of hepatic arterial infusion chemotherapy combined with sintilimab and bevacizumab for initially unresectable hepatocellular carcinoma
The combination of HAIC with sintilimab and bevacizumab represents a safe and effective strategy for tumor conversion. This approach can achieve significant tumor reduction and favorable effects on portal vein tumor thrombus within a short timeframe, facilitating curative resection of liver cancer.
Authors
- Xingyu Chen (ORCID: https://orcid.org/0000-0002-9284-4950)
- Zhu Chen (ORCID: https://orcid.org/0000-0002-9974-0716)
- Chengyou Du (ORCID: https://orcid.org/0000-0003-1977-6362)
- Haiyang Hu (ORCID: https://orcid.org/0000-0002-1816-2134)
- Heng Xiao (ORCID: https://orcid.org/0000-0002-8384-4027)
- Xiang Lan (ORCID: https://orcid.org/0009-0004-5016-1301)
- Kai Chen (ORCID: https://orcid.org/0000-0003-1083-073X)
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- iLiver
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1016/j.iliver.2025.100163
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Natural Science Foundation of Chongqing
- Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission